Literature DB >> 22263060

New molecular targeted therapies for advanced non-small-cell lung cancer.

Míriam Méndez1, Ana Custodio, Mariano Provencio.   

Abstract

Non-small-cell lung cancer (NSCLC) is a uniformly fatal disease and most patients will present with advanced stage. Treatment outcomes remain unsatisfactory, with low long-term survival rates. Standard treatment, such as palliative chemotherapy and radiotherapy, offers a median survival not exceeding 1 year. Hence, considerable efforts have started to be made in order to identify new biological agents which may safely and effectively be administered to advanced NSCLC patients. Two cancer cell pathways in particular have been exploited, the epidermal growth factor receptor (EGFR) and the vascular endothelial growth factor receptor (VEGFR) pathways. However, novel targeted therapies that interfere with other dysregulated pathways in lung cancer are already in the clinic. This review outlines the most promising research approaches to the treatment of NSCLC, discussed according to the specific molecular pathway targeted.

Entities:  

Keywords:  EML4-ALK fusion oncogene; advanced non-small-cell lung cancer; angiogenesis; epidermal growth factor receptor (EGFR); histone deacetylase inhibition; immunotherapy; insulin-like growth factor 1 receptor (IGF-1R); proteasome inhibition; targeted therapies

Year:  2011        PMID： 22263060      PMCID： PMC3256501          DOI： 10.3978/j.issn.2072-1439.2010.12.03

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


  103 in total

1.  Phosphorylated Akt overexpression and loss of PTEN expression in non-small cell lung cancer confers poor prognosis.

Authors:  Jian-Min Tang; Quan-Ying He; Rui-Xia Guo; Xiu-Jun Chang
Journal:  Lung Cancer       Date:  2006-02       Impact factor: 5.705

2.  The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP.

Authors:  Cai-Hong Yun; Kristen E Mengwasser; Angela V Toms; Michele S Woo; Heidi Greulich; Kwok-Kin Wong; Matthew Meyerson; Michael J Eck
Journal:  Proc Natl Acad Sci U S A       Date:  2008-01-28       Impact factor: 11.205

3.  Phase I clinical and pharmacologic study of chronic oral administration of the farnesyl protein transferase inhibitor R115777 in advanced cancer.

Authors:  M Crul; G J de Klerk; M Swart; L J van't Veer; D de Jong; L Boerrigter; P A Palmer; C J Bol; H Tan; G C de Gast; J H Beijnen; J H M Schellens
Journal:  J Clin Oncol       Date:  2002-06-01       Impact factor: 44.544

4.  Inhibition of mammalian target of rapamycin reverses alveolar epithelial neoplasia induced by oncogenic K-ras.

Authors:  Marie Wislez; M Loreto Spencer; Julie G Izzo; Denise M Juroske; Kamna Balhara; Dianna D Cody; Roger E Price; Walter N Hittelman; Ignacio I Wistuba; Jonathan M Kurie
Journal:  Cancer Res       Date:  2005-04-15       Impact factor: 12.701

Review 5.  Ras biochemistry and farnesyl transferase inhibitors: a literature survey.

Authors:  M Crul; G J de Klerk; J H Beijnen; J H Schellens
Journal:  Anticancer Drugs       Date:  2001-03       Impact factor: 2.248

6.  Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer.

Authors:  Joan H Schiller; David Harrington; Chandra P Belani; Corey Langer; Alan Sandler; James Krook; Junming Zhu; David H Johnson
Journal:  N Engl J Med       Date:  2002-01-10       Impact factor: 91.245

7.  A phase II, multicenter, open-label randomized study of motesanib or bevacizumab in combination with paclitaxel and carboplatin for advanced nonsquamous non-small-cell lung cancer.

Authors:  G R Blumenschein; F Kabbinavar; H Menon; T S K Mok; J Stephenson; J T Beck; K Lakshmaiah; K Reckamp; Y-J Hei; K Kracht; Y-N Sun; R Sikorski; L Schwartzberg
Journal:  Ann Oncol       Date:  2011-02-14       Impact factor: 32.976

8.  Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.

Authors:  Tony S Mok; Yi-Long Wu; Sumitra Thongprasert; Chih-Hsin Yang; Da-Tong Chu; Nagahiro Saijo; Patrapim Sunpaweravong; Baohui Han; Benjamin Margono; Yukito Ichinose; Yutaka Nishiwaki; Yuichiro Ohe; Jin-Ji Yang; Busyamas Chewaskulyong; Haiyi Jiang; Emma L Duffield; Claire L Watkins; Alison A Armour; Masahiro Fukuoka
Journal:  N Engl J Med       Date:  2009-08-19       Impact factor: 91.245

9.  A randomized phase II study of bortezomib and pemetrexed, in combination or alone, in patients with previously treated advanced non-small-cell lung cancer.

Authors:  Giorgio V Scagliotti; Paul Germonpré; Leon Bosquée; Johan Vansteenkiste; R Gervais; David Planchard; Martin Reck; Filippo De Marinis; Jin Soo Lee; Keunchil Park; Bonne Biesma; Steven Gans; R Ramlau; Aleusandra Szczesna; A Makhson; G Manikhas; Bruno Morgan; Y Zhu; Kai C Chan; Joachim von Pawel
Journal:  Lung Cancer       Date:  2009-08-18       Impact factor: 5.705

Review 10.  The potential role of histone deacetylase inhibitors in the treatment of non-small-cell lung cancer.

Authors:  Cesare Gridelli; Antonio Rossi; Paolo Maione
Journal:  Crit Rev Oncol Hematol       Date:  2008-04-18       Impact factor: 6.312
View more
  15 in total

1.  Is T790M mutation the key in development of resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs)?

Authors:  Kazuaki Takabe
Journal:  J Thorac Dis       Date:  2011-03       Impact factor: 2.895

2.  Effect of targeted silencing of hTERT mRNA by lentivirus-mediated siRNA on A549 lung cancer cells in vitro.

Authors:  Haibo Tang; Linhu Ge; Wenlong Shao; Yuan Qiu; Dong Cui
Journal:  Mol Biol Rep       Date:  2012-10-09       Impact factor: 2.316

3.  The expression and clinical significance of CLIC1 and HSP27 in lung adenocarcinoma.

Authors:  Wei Wang; Xin Xu; Wujun Wang; Wenlong Shao; Liping Li; Weiqiang Yin; Liangchang Xiu; Mingcong Mo; Jin Zhao; Qingyu He; Jianxing He
Journal:  Tumour Biol       Date:  2011-08-20

4.  Effect of ARHI on lung cancer cell proliferation, apoptosis and invasion in vitro.

Authors:  Xiaohong Wu; Li Liang; Liangliang Dong; Zhe Yu; Xiaoqing Fu
Journal:  Mol Biol Rep       Date:  2012-12-18       Impact factor: 2.316

5.  Efficacy and safety evaluation of icotinib in patients with advanced non-small cell lung cancer.

Authors:  Aiqin Gu; Chunlei Shi; Liwen Xiong; Tianqing Chu; Jun Pei; Baohui Han
Journal:  Chin J Cancer Res       Date:  2013-02       Impact factor: 5.087

6.  Effects of BTG2 on proliferation inhibition and anti-invasion in human lung cancer cells.

Authors:  Sen Wei; Chunfang Hao; Xin Li; Honglin Zhao; Jun Chen; Qinghua Zhou
Journal:  Tumour Biol       Date:  2012-03-06

7.  cDNA microarray analysis of the effect of cantharidin on DNA damage, cell cycle and apoptosis-associated gene expression in NCI-H460 human lung cancer cells in vitro.

Authors:  Te-Chun Hsia; Chien-Chih Yu; Shu-Chun Hsu; Nou-Ying Tang; Hsu-Feng Lu; Chun-Shu Yu; Shin-Hwar Wu; Jaung-Geng Lin; Jing-Gung Chung
Journal:  Mol Med Rep       Date:  2015-03-24       Impact factor: 2.952

8.  Genistein enhances the effect of cisplatin on the inhibition of non-small cell lung cancer A549 cell growth in vitro and in vivo.

Authors:  Dezhi Liu; Ling Yan; Lan Wang; Weicheng Tai; Weili Wang; Changbin Yang
Journal:  Oncol Lett       Date:  2014-10-09       Impact factor: 2.967

9.  Dual targeting of the insulin-like growth factor and collateral pathways in cancer: combating drug resistance.

Authors:  Joseph A Ludwig; Salah-Eddine Lamhamedi-Cherradi; Ho-Young Lee; Aung Naing; Robert Benjamin
Journal:  Cancers (Basel)       Date:  2011-07-26       Impact factor: 6.639

10.  Enhancement of gefitinib-induced growth inhibition by Marsdenia tenacissima extract in non-small cell lung cancer cells expressing wild or mutant EGFR.

Authors:  Shu-Yan Han; Hui-Rong Ding; Wei Zhao; Fei Teng; Ping-Ping Li
Journal:  BMC Complement Altern Med       Date:  2014-05-22       Impact factor: 3.659
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.